Overcoming immunotherapy resistance in pMMR/MSS colorectal cancer: multi-target combination strategies

Colorectal cancer (CRC) ranks among the leading causes of cancer-related mortality worldwide, yet the vast majority of metastatic cases, classified as proficient mismatch repair and microsatellite-stable(pMMR/MSS), derive little benefit from immune checkpoint inhibitors (ICIs). This primary resistance stems from convergent tumor-intrinsic alterations, including deficient antigen presentation, Wnt/β-catenin-driven T cell exclusion, and metabolic reprogramming, alongside microenvironmental barriers such as immunosuppressive myeloid cell infiltration, stromal exclusion, and gut microbiota dysbiosis. Here, we synthesize the multi-layered resistance mechanisms that render pMMR/MSS CRC refractory to immunotherapy and critically evaluate the expanding portfolio of combination strategies designed to overcome them. We categorize these approaches into eight domains: anti-angiogenic agents combined with ICIs, MAPK pathway inhibitors paired with immunotherapy, epigenetic modulators, next-generation immune checkpoint targets (LAG-3, TIM-3, TIGIT, CD47), stimulator of interferon genes agonists and oncolytic viruses, cellular therapies and bispecific antibodies, personalized neoantigen vaccines, and radiotherapy-immunotherapy combinations. Throughout, early-phase response signals are contrasted with the negative randomized trials IMblaze370 and LEAP-017, neither of which improved overall survival in pMMR/MSS disease. We further discuss biomarker-guided stratification frameworks integrating molecular profiling (BRAF, KRAS, HER2 status), circulating tumor DNA dynamics, stromal signatures, and microbiome composition, and summarize key clinical trials in a structured evidence table. We conclude by outlining key translational gaps: validated predictive biomarkers, optimized sequencing strategies, and rationally designed trial endpoints. By mapping the mechanistic rationale for each combinatorial approach onto the specific resistance circuitry it targets, this review provides a structured framework for advancing pMMR/MSS CRC toward clinically meaningful immunotherapy responses.

Authors

Institutions

Publication Details

Journal
Journal of Cancer Metastasis and Treatment
Published
2026-11-20
DOI
https://doi.org/10.20517/2394-4722.2026.40
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Overcoming immunotherapy resistance in pMMR/MSS colorectal cancer: multi-target combination strategies

Jian Liao, Wei Chen
2 links
Journal of Cancer Metastasis and Treatment
Cancer Immunotherapy and Biomarkers
article

Overcoming immunotherapy resistance in pMMR/MSS colorectal cancer: multi-target combination strategies

Jian Liao, Wei Chen
article en

Abstract

Colorectal cancer (CRC) ranks among the leading causes of cancer-related mortality worldwide, yet the vast majority of metastatic cases, classified as proficient mismatch repair and microsatellite-stable(pMMR/MSS), derive little benefit from immune checkpoint inhibitors (ICIs). This primary resistance stems from convergent tumor-intrinsic alterations, including deficient antigen presentation, Wnt/β-catenin-driven T cell exclusion, and metabolic reprogramming, alongside microenvironmental barriers such as immunosuppressive myeloid cell infiltration, stromal exclusion, and gut microbiota dysbiosis. Here, we synthesize the multi-layered resistance mechanisms that render pMMR/MSS CRC refractory to immunotherapy and critically evaluate the expanding portfolio of combination strategies designed to overcome them. We categorize these approaches into eight domains: anti-angiogenic agents combined with ICIs, MAPK pathway inhibitors paired with immunotherapy, epigenetic modulators, next-generation immune checkpoint targets (LAG-3, TIM-3, TIGIT, CD47), stimulator of interferon genes agonists and oncolytic viruses, cellular therapies and bispecific antibodies, personalized neoantigen vaccines, and radiotherapy-immunotherapy combinations. Throughout, early-phase response signals are contrasted with the negative randomized trials IMblaze370 and LEAP-017, neither of which improved overall survival in pMMR/MSS disease. We further discuss biomarker-guided stratification frameworks integrating molecular profiling (BRAF, KRAS, HER2 status), circulating tumor DNA dynamics, stromal signatures, and microbiome composition, and summarize key clinical trials in a structured evidence table. We conclude by outlining key translational gaps: validated predictive biomarkers, optimized sequencing strategies, and rationally designed trial endpoints. By mapping the mechanistic rationale for each combinatorial approach onto the specific resistance circuitry it targets, this review provides a structured framework for advancing pMMR/MSS CRC toward clinically meaningful immunotherapy responses.

Journal of Cancer Metastasis and Treatment
Guilin Medical University (CN)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon